What are Vertex Pharmaceuticals's total assets?

Vertex Pharmaceuticals (VRTX) holds $26.5B in total assets, up 15.8% year over year.

How much debt does Vertex Pharmaceuticals have?

Vertex Pharmaceuticals carries $2.0B in total debt against $19.4B of shareholders' equity, a debt-to-equity ratio of 0.10.

How much cash does Vertex Pharmaceuticals have?

Vertex Pharmaceuticals holds $5.5B in cash and equivalents.

Can Vertex Pharmaceuticals cover its short-term obligations?

Its current ratio is 3.02 — current assets exceed current liabilities.

Where does Vertex Pharmaceuticals's balance sheet data come from?

Every line is extracted from Vertex Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

Vertex Pharmaceuticals VRTX Balance Sheet Statement

Income Statement Balance Sheet Cash Flow Ratios Segments

Quarterly Annual TTM

YoY

Simplified Detailed

	FY'25	FY'24	FY'23	FY'22
Cash and cash equivalents	$5.09B+11.3%	$4.57B-55.9%	$10.37B+235%	$3.1B-6.1%
Short-term investments	$1.52B-1.5%	$1.55B+82.1%	$849.2M+209%	$274.5M-62.4%
Restricted cash	$3M+15.4%	$2.6M-18.8%	$3.2M-60.0%	$8M+56.9%
Accounts receivable, net	$2.05B+27.6%	$1.61B+2.9%	$1.56B+8.4%	$1.44B+26.9%
Inventories	$1.69B+39.9%	$1.21B+63.2%	$738.8M+60.4%	$460.6M+30.4%
Raw materials	$259.8M+3.1%	$252M+220%	$78.7M+107%	$38.1M-10.1%
Work in process	$1.2B+55.7%	$768.8M+46.4%	$525.1M+101%	$260.7M+16.4%
Prepaid expenses and other current assets	$853.3M+28.2%	$665.7M+6.7%	$623.7M+12.7%	$553.5M+1.4%
Total current assets	$11.2B+16.7%	$9.6B-32.2%	$14.14B+6.9%	$13.23B+38.4%
Goodwill	$1.09B0.0%	$1.09B0.0%	$1.09B0.0%	$1.09B+8.6%
Equity securities	$16.6M-54.6%	$36.6M-20.4%	$46M-60.6%	$116.8M-49.4%
Total assets	$25.64B+13.8%	$22.53B-0.9%	$22.73B+25.2%	$18.15B+35.1%
Accounts payable	$461.7M+11.8%	$413M+13.2%	$364.9M+20.1%	$303.9M+55.8%
Total current liabilities	$3.86B+8.3%	$3.56B+0.5%	$3.55B+29.4%	$2.74B+28.0%
Operating lease liabilities, non-current	$1.85B+19.6%	$1.54B+343%	$348.6M-8.1%	$379.5M+0.6%
Other non-current liabilities	$1.27B+25.1%	$1.01B+15.6%	$877.7M+28.0%	$685.8M+126%
Total liabilities	$6.98B+13.9%	$6.12B+18.9%	$5.15B+21.5%	$4.24B+27.2%
Retained earnings	$13.56B+41.2%	$9.61B-5.3%	$10.14B+55.5%	$6.52B+104%
Accumulated other comprehensive income (loss)	-$15.9M-112%	$127.8M+994%	-$14.3M-1,888%	$800K-95.0%
Total stockholders' equity	$18.67B+13.7%	$16.41B-6.7%	$17.58B+26.4%	$13.91B+37.7%
Total liabilities and stockholders' equity	$25.64B+13.8%	$22.53B-0.9%	$22.73B+25.2%	$18.15B+35.1%
AFS and Trading Securities - Unrealized Loss Position (>=12 Months)	——	——	——	——
AFS and Trading Securities - Unrealized Loss Position (>=12 Months) Fair Value	——	——	——	——
AFS and Trading Securities - Unrealized Loss Position Fair Value	——	——	——	——
Finished goods	$230.1M+24.6%	$184.6M+36.7%	$135M-16.6%	$161.8M+86.6%
Short- term Investments	$1.52B-1.5%	$1.55B+82.1%	$849.2M+209%	$274.5M-62.4%
Current Equity Amortized Cost	$25M-65.3%	$72.1M0.0%	$72.1M-30.9%	$104.4M+50.4%
Equity Securities (FV-NI) - Cost Basis	$25M-65.3%	$72.1M0.0%	$72.1M-30.9%	$104.4M+50.4%
Deferred Tax Assets and Other Non-Current Assets	$1.24B+23.7%	$999.3M+11.6%	$895.3M+119%	$409.6M+270%
Equity Amortized Cost	$25M-65.3%	$72.1M0.0%	$72.1M-30.9%	$104.4M+50.4%
Investments - Cost Basis	$25M-65.3%	$72.1M0.0%	$72.1M-30.9%	$104.4M+50.4%
Net Investment in Lease	$1.56B+15.2%	$1.36B+362%	$293.6M-15.5%	$347.4M+5.2%
Deferred tax assets	$2.9B+24.3%	$2.33B+28.6%	$1.81B+45.3%	$1.25B+33.4%
Other intangible assets—net	$424.2M-48.6%	$825.9M-1.7%	$839.9M+39.1%	$603.6M+50.9%
Long- term Investments	$5.71B+11.8%	$5.11B+104%	$2.5B+2,126%	$112.2M—
Operating lease right-of-use assets	$1.56B+15.2%	$1.36B+362%	$293.6M-15.5%	$347.4M+5.2%
Other non-current assets	$1.24B+23.7%	$999.3M+11.6%	$895.3M+119%	$409.6M+270%
Property, plant and equipment, net	$1.52B+23.8%	$1.23B+5.9%	$1.16B+4.6%	$1.11B+1.3%
Operating Lease Right-of-Use Assets in Other Assets	$1.56B+15.2%	$1.36B+362%	$293.6M-15.5%	$347.4M+5.2%
Software and Technology Licenses, Net	$1.24B+23.7%	$999.3M+11.6%	$895.3M+119%	$409.6M+270%
Other Commercial Liabilities	$2.97B+6.5%	$2.79B+5.0%	$2.66B+24.9%	$2.13B+26.7%
Accrued Liabilities, Current	$2.97B+6.5%	$2.79B+5.0%	$2.66B+24.9%	$2.13B+26.7%
Other accrued liabilities	$428.3M+18.0%	$363M-31.1%	$527.2M+69.2%	$311.5M+16.1%
Total debt	$2.04B+16.4%	$1.75B+104%	$859M-4.5%	$899.7M-7.0%
AFS and Trading Securities - Unrealized Loss Position (>=12 Months) Accumulated Loss	——	——	——	——
Additional paid-in capital	$5.12B-23.3%	$6.67B-10.4%	$7.45B+0.9%	$7.39B+7.3%
Common stock; $0.001 par value; 6,000 shares authorized; 3,755 and 3,751 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively	$2.5M-3.8%	$2.6M0.0%	$2.6M0.0%	$2.6M+4.0%
Preferred stock; $0.001 par value; 100 shares authorized; no shares issued and outstanding	$0—	$0—	$0—	$0—
Investments - Gross Unrealized Losses	——	——	——	——
Share Repurchase Program - Amount Remaining	——	——	——	——
Cumulative Cost Basis	$25M-65.3%	$72.1M0.0%	$72.1M-30.9%	$104.4M+50.4%
Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax	——	——	——	——
Business Combination, Contingent Consideration, Liability	$79M+2.7%	$76.9M-0.6%	$77.4M-40.0%	$129M-30.8%
Fair Value	$2.78B+64.7%	$1.69B-76.0%	$7.03B-4.6%	$7.37B—
Cash Equivalents And Debt Securities, Available for Sale	$2.78B+64.7%	$1.69B-76.0%	$7.03B-4.6%	$7.37B—
Cash Equivalents, Debt and Equity Securities, Cost	$9.98B+19.3%	$8.37B-19.5%	$10.39B—	——
Total cash equivalents and marketable securities, Fair Value	$10.01B+20.1%	$8.34B-19.6%	$10.38B—	——
Total cash equivalents and marketable securities, Gross Unrealized Gains	$44.3M+94.3%	$22.8M+43.4%	$15.9M—	——
Cash Equivalents, Debt and Equity Securities, Unrealized Loss	$9M-81.7%	$49.1M+65.3%	$29.7M—	——
Common stock, par value (in dollars per share)	$0.010.0%	$0.010.0%	$0.010.0%	$0.010.0%
Common stock, shares authorized (in shares)	500M0.0%	500M0.0%	500M0.0%	500M0.0%
Common stock, shares issued (in shares)	254M-1.1%	256.9M-0.3%	257.7M+0.3%	257M+1.0%
Common Stock, Shares, Outstanding	254M-1.1%	256.9M-0.3%	257.7M+0.3%	257M+1.0%
Contingent liabilities	$0—	$0—	$0—	$0—
Contract with Customer, Liability	$171.8M-16.9%	$206.8M+21.4%	$170.3M+6.7%	$159.6M-7.0%
Debt Securities, Available-for-Sale, Allowance for Credit Loss	——	——	——	——
Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss	——	——	——	——
12 months or more	——	——	——	——
Debt Securities, Available-for-Sale, Unrealized Loss Position	——	——	——	——
Debt and Equity Securities, Cost	$7.2B+7.8%	$6.68B+98.8%	$3.36B+798%	$374.4M-34.2%
Fair Value	$7.24B+8.7%	$6.65B+98.8%	$3.35B+766%	$386.7M-47.0%
Gross  Unrealized  Gains	$44.3M+94.3%	$22.8M+43.4%	$15.9M-48.9%	$31.1M-81.4%
Debt and Equity Securities, Unrealized Loss	$9M-81.7%	$49.1M+65.3%	$29.7M+58.0%	$18.8M+208%
Cost	$25M-65.3%	$72.1M0.0%	$72.1M-30.9%	$104.4M+50.4%
Finite-Lived Intangible Assets, Accumulated Amortization	$46.1M+97.0%	$23.4M—	——	——
Indemnification claims	——	——	——	——
Indefinite- lived intangible impairment	$470.3M-44.6%	$849.3M—	——	——
Loss Contingency Accrual	$0—	$0—	——	——
Preferred Stock, Par or Stated Value Per Share	$0.010.0%	$0.010.0%	$0.010.0%	$0.010.0%
Preferred Stock, Shares Authorized	1M0.0%	1M0.0%	1M0.0%	1M0.0%
Preferred Stock, Shares Issued	0—	0—	0—	0—
Share Repurchase Program, Remaining Authorized, Amount	——	——	——	——
Amount that if recognized, would affect the effective tax rate or regulatory liability	$436.6M+27.9%	$341.4M+18.3%	$288.7M+38.5%	$208.5M+61.0%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Ask your AI about Vertex Pharmaceuticals.

Connect your AI assistant and get a quick read on the numbers, right in your chat.

Connect your AI

Claude

Questions, answered.

What are Vertex Pharmaceuticals's total assets?: Vertex Pharmaceuticals (VRTX) holds $26.5B in total assets, up 15.8% year over year.
How much debt does Vertex Pharmaceuticals have?: Vertex Pharmaceuticals carries $2.0B in total debt against $19.4B of shareholders' equity, a debt-to-equity ratio of 0.10.
How much cash does Vertex Pharmaceuticals have?: Vertex Pharmaceuticals holds $5.5B in cash and equivalents.
Can Vertex Pharmaceuticals cover its short-term obligations?: Its current ratio is 3.02 — current assets exceed current liabilities.
Where does Vertex Pharmaceuticals's balance sheet data come from?: Every line is extracted from Vertex Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.